Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — AusBioInvest 2024
19 slides from Arovella Therapeutics's conference presentation, Oct 29, 2024
Slide 1: AusBioInvest Presentation ASX Release
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 29 October 2024 AUSBIOINVEST PRESENTATION MELBOURNE, AUSTRALIA 29 October 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleas
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cance
Slide 3: AusBioInvest 2024
ASX:ALA For personal use only AusBioInvest 2024 ASX: ALA October 2024
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment 4. Whilst this presentation is based on information from sources which are advice. The presentation is not intended to be comprehensive or provide all considered reliable, no representation or warranty, expres
Slide 5: Arovella's strengths
Arovella’s strengths Off-the-Shelf iNKT Lead Product Addressing Key Strong For personal use only Cell Platform Advancing to Clinic Unmet Need Leadership Group Developing off-the-shelf iNKT ALA-101, potential treatment Our iNKT cell platform is Leadership team and Board cell therapies to target blood
Slide 6: Financial overview
Financial overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA $0.20 For personal use only Market capitalisation1 $184.84 million 40,000,000 $0.18 Shares on issue 1,056.2 million $0.16 52-week low / high1 $0.080 / $0.205 $0.14 30,000,000 Pro-forma Cash Balance (30 Sep, 2024)2 $
Slide 7: Recent cell therapy transactions
Recent cell therapy transactions1 Upfront Milestones Total deal Date Type of deal Acquirer/Licensee Target/Licensor Cell Type Stage (US$M) (US$M) value (US$M) Research May-24 T cell TBD $50 $550 $600 collaboration For personal use only Dec-23 Acquisition T Cell Phase 1b $1,000 $200 $1,200 Collaborat
Slide 8: How original CAR-T cell therapies work
How original CAR-T cell therapies work CAR-T cell therapy is personalised medicine T cells = immune cell For personal use only T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ To generate autologous CAR-T cells, T cells are
Slide 9: Current CAR-T technology challenges and ALA's solution
Current CAR-T technology challenges ALA’s solution: One CAR-T product only treats the patient who supplied the T cells One CAR-iNKT batch from Manufacturing & supply a healthy donor treats For personal use only T cell chain costs are high multiple patients T cell Each T cells can be manufacturing co
Slide 10: Introducing invariant Natural Killer T (iNKT) cells
Introducing invariant Natural Killer T (iNKT) cells Bridging the innate and adaptive immune system For personal use only Innate Immunity Adaptive Immunity ASX:ALA 8
Slide 11: iNKT cells represent a next-generation cell therapy
iNKT cells represent a next-generation cell therapy Properties make them ideal for use in cell therapy Strong safety profile For personal use only Don’t cause graft versus host disease (GvHD) Innate Front line of the human Immunity immune system Bridge innate & adaptive immune responses Contai
Slide 12: A differentiated position
A differentiated position T cell and NK cell sectors are competitive For personal use only T cell iNKT cell NK cell Companies with T cell, NK cell, or iNKT cell therapy programs. Source: Company analysis based on public information ASX:ALA 10
Slide 13: Arovella's iNKT cell strategy
Arovella’s iNKT cell strategy Incorporating world class IP to target a range of tumour types For personal use only Foundation IP Armouring Novel CARs Regulatory Know-How Unique process to technology Unique CARs strategy Process-specific transduce iNKT cells Complementary for targeting 12-year market
Slide 14: Arovella's path to patient
Arovella’s path to patient TECHNOLOGY PRE-CLINICAL LENTIVIRUS MANUFACTURING FDA (IND) / PHASE 1 PHASE 2 PRODUCT ACQUISITION CONFIRMATION MANUFACTURING PLATFORM TGA (CTA) CLINICAL TRIAL CLINICAL TRIAL For personal use only CD19-iNKT Blood Cancer FY2025 CLDN18.2-iNKT Gastric Cancer CAR-iNKT Other Canc
Slide 15: Arovella's expanding pipeline
Arovella’s expanding pipeline For personal use only ASX:ALA 13
Slide 16: Upcoming milestones for FY2025
Upcoming milestones for FY2025 July July 2024 2025 For personal use only Complete cGMP manufacture for Phase 1 and IND-enabling studies Complete preparatory activities for Phase 1 study, preparation of Arovella is funded to dose ALA-101 regulatory dossier, engagement with clinical sites and KOLs
Slide 17: Summary
Summary Novel allogeneic Lead product progressing CAR-iNKT cell platform to clinical trials For personal use only iNKT cells serve as an excellent platform ALA-101, a potential treatment for to develop allogeneic, or “off-the-shelf”, CD19-expressing blood cancers, is cell therapies to treat cancer b
Slide 18: Thank You
ASX:ALA For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: investor@arovella.com Mobile: +61 403 468 187
Slide 19: Cell therapy deal references
Cell therapy deal references 1. https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with- Imugene-for-Azer-Cel-in-Cancer 2. https://www.astellas.com/en/news/28271 3. https://www.jnj.com/janssen-enters-worldwide-collaboration-and-license-agre